New PRECISIONheor-led Study Examines Challenges in Capturing Economic Burden of Cancer

Congratulations to Suepattra May-Slater and the PRECISIONheor team for their contributions to a impactful study just published in the journal MDM Policy and Practice. The paper, entitled: "Estimating Productivity Loss from Breast and Non–Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method" outlines the challenges in truly capturing the economic burden of cancer for both patients and their caregivers. The authors also suggest the need for more support in the workplace for these individuals, and a holistic approach to accounting for these impacts in treatment decision making.

LEARN MORE

New PRECISIONheor-led Study Examines Challenges in Capturing Economic Burden of Cancer2022-08-10T13:55:37-04:00

Incorporating Disease Transmission Dynamics Into Value Assessment

With focus in the COVID-19 pandemic shifting to treatments and managing severe forms of the disease, it's important to understand how health economists capture these dynamics to estimate the value of antiviral treatments. Precision's Jacquelyn W. Chou, Marissa Baker-Wagner, Marlon Graf, Zachary Heim, and T. Joseph Mattingly II provide recommendations for aligning the actual practice of value assessment of antivirals with best practice guidelines

LEARN MORE

Incorporating Disease Transmission Dynamics Into Value Assessment2022-08-01T10:28:59-04:00

Three Essential Tactics for Successful Drug Commercialization

One of the top tradeoffs faced by clinical stage biotech and pharmaceutical firms in raising capital to fund their clinical trial programs is the question of when and how to build a commercialization strategy, including navigating the complex work of securing market access. Precision's Ross Maclean and co-author Liz Turner discuss three high-value tactics that should be conducted early to avoid costly missteps that could impact product success.

LEARN MORE

Three Essential Tactics for Successful Drug Commercialization2022-08-01T15:02:35-04:00

Seven Strategies for Succeeding as a Small Fish in a Big Pond

Emerging biotech organizations have had to become both resourceful and creative since the start of the COVID-19 pandemic. At the same time, Big Pharma and the medical device firms have turned around COVID-19 diagnostics, vaccines, and therapeutics at a stunningly impressive pace. The pressure on emerging and small biotech companies to do more with less and maximize results is only projected to continue. Precision's Ross Maclean and co-author Liz Turner identify seven key attributes that favor the smaller biotech.

LEARN MORE

Seven Strategies for Succeeding as a Small Fish in a Big Pond2022-08-01T09:58:17-04:00

Insights90: Marlon Graf

In these past few years, life has been filled with uncertainty. Listen as Precision’s Marlon Graf discusses how PRECISIONheor finds ways to deal with uncertainty in healthcare decision making in this Insights90.

LEARN MORE

Insights90: Marlon Graf2022-06-09T09:49:35-04:00

Equity in Clinical Research: From Trials to Treatment

Many pharmaceutical and medical device companies have made commitments to address health inequities as they exist in the realm of clinical trials. Precision's Alice Pressman co-authors this article discussing some of the obstacles, solutions, and implications for widespread efforts to improve health equity throughout the clinical research cycle. Learn More: https://lnkd.in/gxZKf_C2https://lnkd.in/gxZKf_C2

LEARN MORE

Equity in Clinical Research: From Trials to Treatment2022-07-29T23:28:18-04:00